Adeno-associated viral (AAV) vectors promote long-term gene transfer into muscle in many animal species. Increased expression levels may be obtained by using alternative serotypes in combination with repeated administrations. Here we compared AAV vectors based on serotypes 1, 2 and 5 in immunocompetent mice and assessed the feasibility of multiple administrations of either identical (readministration) or different (cross-administration) serotype-based vectors. A 1-year-long dose-response study confirmed the superiority of recombinant (r)AAV1, achieving transduction levels 5 to 10-fold higher than rAAV2 and rAAV5 in mouse skeletal muscle, respectively. Repeated administration demonstrated that increased gene transfer level was achieved with a second injection of rAAV1 following the first administration of rAAV2 or rAAV5. A readministration study with a vector encoding a different gene allowed the evaluation of gene expression from the second vector only. All three rAAVs were inhibited when the animals were previously exposed to the same serotype. In contrast, no significant change in gene expression from the second vector was observed in cross-administration. A humoral immune response was elicited against the viral capsid for all three serotypes following the initial exposure. Neutralizing antibody (NAB) levels correlated with the vector dose injected. No significant cross-reactivity of NAB from a given serotype toward another was observed in vitro. These data provide the first direct comparative evaluation of re-and cross-administration of rAAV1, rAAV2 and rAAV5 in muscle, and further indicate that rAAV1 is capable of transducing muscle tissue when cross-administered.
Introduction
Recombinant adeno-associated viruses (rAAV) are highly attractive vectors for human gene transfer since they can direct long-term expression without associated pathogenicity in a number of tissues including muscle. [1] [2] [3] [4] [5] Skeletal muscles represent an essential target for numerous clinical applications such as neuromuscular disorders 6 or clinical conditions in which a reservoir strategy for a therapeutic protein is envisaged. 7, 8 Efficient fiber transduction following rAAV2-mediated gene transfer, although initially judged to be very encouraging, 9 has been disappointing in further studies in large animal models and in humans, due to the immune reaction and insufficient level of gene expression. 10 The overall goal of correcting chronic diseases caused by genetic deficiencies with viral vectors is limited by the necessity of achieving stable, high-level gene expression, potentially requiring vector readministration, in order to treat patients throughout their lives. However, host immune responses elicited by the vector can interfere with further vector administration. Several studies have shown that a single rAAV2 injection can lead to the production of neutralizing antibodies (NAB) against the vector. 9, 11 This host humoral immune response directed against the capsid proteins, but not the transgene product, is responsible for the failure of successful rAAV2 readministration. [12] [13] [14] Immunosuppression strategies have been successfully applied in animal models to circumvent antivector immune responses after intramuscular administration, 11, 12 although they might not be applicable in all clinical settings, especially those concerning individuals with seriously compromised health conditions.
The limitations of efficient gene delivery by rAAV2 can be attributed to several factors. First, the level of expression following rAAV2 administration is insufficient to reach a therapeutic threshold, especially in large animals. This has led to the development of alternative serotypes, and AAV1, its close relative AAV6 and more recently AAV8 have been shown to be far more efficient than rAAV2 in this respect. [15] [16] [17] [18] [19] [20] Second, some of this limitation has been attributed to an immune response against rAAV2 following the previous exposure. 11 A broad pre-existing humoral immunity to wild type AAV2 in humans has been reported, indicating that more than 80% humans are seropositive, 21, 22 which may severely impair the success of a gene transfer protocol in clinical trials.
As a consequence, a more efficient way to increase AAV-mediated gene transfer and bypass the immunity to AAV2-derived vectors has emerged with the development of AAV vectors from alternative serotypes, similar to the approach developed for adenoviral vectors. 23 Of the 11 primate AAV strains described and used to derive vectors, [24] [25] [26] [27] [28] [29] [30] rAAV1 and rAAV5 have been shown to strongly improve muscle gene transfer efficiency compared to rAAV2. 15, 31, 32 Because they are immunologically distinct, these serotypes can provide an alternative to the AAV2 serotype and avoid a pre-existing immune response. The alternative serotypes might also open up the possibility for repeated vector administration. It has been demonstrated that antibodies to AAV1 and AAV5 are present in humans at a frequency lower than those against AAV2. 24, 32, 33 Initial cross-administration studies with different serotypes gave promising results: rAAV1 was successfully administered to mice previously treated with rAAV2 and vice versa, 24 and similar results were obtained with rAAV5 cross-administered with rAAV2 in immunocompetent mice. 32 In this study, we further expanded these studies and carried out a complete long-term comparison of rAAV1, rAAV2 and rAAV5 for muscle gene transfer. We used the pseudotyping strategy, which allows for the generation of vectors consisting of AAV2 Inversed Terminal Repeat (ITR)-derived genomes packaged into an AAV1 or AAV5 capsid. We performed a dose-response and time-course analysis of the efficiency of rAAV1, rAAV2 and rAAV5 to mediate transduction via intramuscular delivery in mice, and further demonstrated the superiority of rAAV1 in achieving high-level transgene expression. We also investigated the host humoral response against the vector and its consequences on the efficiency of multiple administrations. Repeated administration was performed using identical or alternative AAV vector serotypes encoding the same transgene murine secreted alkaline phosphatase (muSEAP) to evaluate the possibility of maintaining or increasing muscle transduction. Our results show enhanced gene transfer level by rAAV1 when the animal has been previously exposed to a rAAV2 or rAAV5. No increased expression was seen after re-injecting rAAV2 and rAAV5 in animals primarily exposed to rAAV2, rAAV5 or rAAV1. We then asked whether the second administration was efficient or if the vector was the target of a specific immune inhibition. We performed another repeated administration study with the second vector encoding a different protein (luciferase). Our results demonstrate that full expression can be obtained from rAAV1, rAAV2 and rAAV5 after a primary injection of a non-identical serotype, indicating that no significant cross-neutralization between rAAV1, rAAV2 and rAAV5 occurs after muscular delivery. On the contrary, repeated administration of the identical serotype led to a decreased gene expression, which was further confirmed by the level of NAB present in blood.
Results
Long-term persistence of rAAV1, rAAV2 and rAAV5 and the humoral response following intramuscular administration
The long-term efficiencies of pseudotyped rAAV1, rAAV2 or rAAV5 bearing the CMV-muSEAP cassette (see Materials and methods) were first compared in muscle. Three doses of 2.2 Â 10 8 , 6.6 Â 10 8 and 2 Â 10 9 viral genomes (vg) were injected into the tibialis anterior (TA) of adult Balb/c mice. Transgene expression was evaluated up to one year after injection by quantification of the secreted muSEAP activity and histochemical detection to document the pattern of expression at the muscle fiber level. By 3 weeks post-injection of rAAV1, rAAV2 and rAAV5, the highest doses of rAAV led to a dose dependent high level of expression that was sustained for a year (Figure 1a ). Recombinant AAV1 led to the highest level of transduction, followed by rAAV5 (5-fold lower) and rAAV2 (12-fold lower). Of note, the kinetics of transduction for rAAV1 appeared accelerated in comparison to rAAV2 and rAAV5. The lowest dose (2.2 Â 10 8 vg/muscle) led to a level of gene transfer close to background with all vectors.
Histological analysis was performed to determine the transduction pattern in myofibers. Sections of injected muscles were stained for muSEAP expression at 12 months. The patterns correlated well with the quantitative data, both for the dose-response study and the comparative efficiency levels, with rAAV1 displaying the highest pattern of gene expression, followed by rAAV5 and rAAV2 (Figure 1b) . At the lowest vector dose, the number of positive fibers was very low, confirming the secretion data. Hematoxylin-eosin staining showed no evidence of early inflammation due to injection (day 7, not shown) or alteration of the muscle architecture at one year post-injection.
If readministration is needed in a therapeutic protocol, a major issue is the occurrence of an immune response toward both the vector and the transgene product. In this study, we focused on the capsid induced humoral immune response. We first asked whether gene transfer with AAV vectors was associated with the generation and the persistence of a humoral immune response against AAV1, AAV2, and AAV5 particles by quantifying the NAB in mice one year after injection. Neutralizing antibodies from injected mice were titrated in vitro by a virus neutralization assay, using the sera from the same animals as those analyzed in Figure 1 . Intramuscular injection of rAAV1 and rAAV2 led to the production of NAB that was still detectable 1 year later, while no such humoral immune response was detected following rAAV5 administration. For rAAV1 and rAAV2, increase in NAB titer was correlated with the viral dose injected (Figure 2) . Interestingly, the anti-vector NAB levels (AAV24AAV14AAV5) were not correlated with transduction efficiencies (AAV14AAV54AAV2) observed at 1 year post-injection.
Multiple administrations of rAAV1, rAAV2 and rAAV5 encoding the same gene
We then evaluated the possibility of increasing gene expression by a second vector injection after a short interval of time, using either the same or a different serotype as the initial one. Two sequential intramuscular injections in the right and then in the left muscle of 2 Â 10 9 vg of rAAV1, rAAV2 or rAAV5 expressing muSEAP were performed at day 0 and day 30, in all combinations. The level of muSEAP was measured throughout the experiment up to day 60 ( Figure 3) . No significant increase of expression could be induced upon This was expected, because even in the absence of immune response, only a 2-fold increase of gene transfer levels could be theoretically observed, a variation not clearly visible with the assay used here. We did not observe increased gene transfer with rAAV5 in mice previously injected with rAAV2 ( Figure 3c ), although rAAV5 is slightly more efficient than rAAV2 (2 to 3-fold, Figure 1 ). Again, it is likely that the reporter system sensitivity does not allow unambiguous detection of such variation. However, we cannot exclude here that this absence of improved efficiency could be caused by an immune reaction toward the capsid proteins and the transgene product. However, we did not observe destruction of the previously transduced fibers (histology not shown), nor did we see a decline of the level of expression that would be suggestive of such destruction due to a strong immune reaction.
Recombinant AAV1 was previously demonstrated to be 12-fold and 5-fold more efficient for gene transfer than rAAV2 and rAAV5, respectively ( Figure 1 ). In this crossadministration experiment, administration of rAAV1 after rAAV2 or rAAV5 led to an improvement in gene expression of about 5-fold (Figure 3 ), suggesting in this case that the second injection was efficient.
Multiple administrations of rAAV1, rAAV2 and rAAV5 encoding different genes In order to evaluate the level of gene expression originating from the second injection and then to evaluate a possible inhibition of the vector, we performed double-injection experiments in which the second vector encoded a different reporter product (luciferase) under the control of the CMV promoter. We Multiple administrations of rAAV in muscle C Rivière et al then evaluated gene transfer efficiency of the second Luc-vector. The first intramuscular injection was performed with rAAV1, rAAV2 or rAAV5 encoding the muSEAP (2 Â 10 9 vg/muscle) followed by a second administration 30 days later, with an identical (readministration) or an alternative (cross-administration) serotype-based vector expressing the luciferase (2 Â 10 9 vg/muscle). Circulating muSEAP measured throughout the experiment yielded data similar to that obtained previously and was not affected by the secondary vector administration, in all combinations (not shown).
The luciferase expression resulting from the second rAAV administration was measured in muscle lysates 30 days after the second injection (60 days after the first injection). Due to in vivo variation, this experiment was repeated three times (n ¼ 4 for each experiment). A typical result is shown in Figure 4 . For the three vectors, readministration led to a decrease of luciferase levels originating from the second vector (rAAV A followed by rAAV A ) compared to animals that received phosphatebuffered saline (PBS) in the first injection (PBS+rAAV A ). For all vectors, this reduction was within 1-2 log in all reinjected mice compared to control animals that received PBS as a primary injection (Figure 4 ). An initial exposure to a given serotype vector (A) did not lead to a decrease in gene transfer from a second vector of different serotype (B) (compare 'PBS+rAAV B ' with 'rAAV A + rAAV B ', Figure 4 ). The decrease of transduction efficiency due to readministration (rAAV A followed by rAAV A ) compared to cross-administration (non-rAAV A followed by rAAV A ) was statistically significant (two-factor analysis of variance (ANOVA) test, see Materials and methods), Po0.001 for rAAV1, rAAV2 and rAAV5. We did not see a statistical difference in the extent of self-inhibition between the different serotype vectors, although a trend to a less marked self-inhibition was observed with rAAV1. It should be noted that the expression level after rAAV1+rAAV1 is still far above the background, which is not the case for double injection of rAAV2 and rAAV5 (Figure 4 ).
Altogether these results indicate that there is a specific inhibition of the vector following the readministration of the same serotype. Furthermore, the result of crossadministration combinations showed a minimal, if any, immune cross-reactivity between rAAV1, rAAV2 and rAAV5 viral capsids.
Neutralizing antibody response is boosted by repeated intramuscular administration of the same serotype To investigate how the humoral anti-vector response was affected by the readministration procedure, NAB titers were determined after a single injection (rAAV A at 30 Figure 3 Multiple administrations of rAAV-muSEAP in skeletal muscle. An initial injection of (a) phosphate-buffered saline (PBS) (n ¼ 28), (b) 2 Â 10 9 vg of rAAV1-muSEAP (n ¼ 28), (c) 2 Â 10 9 vg of rAAV2-muSEAP (n ¼ 28), (d) 2 Â 10 9 vg of rAAV5-muSEAP (n ¼ 28) was performed into the TA of Balb/c mice. For each group, four mice were subjected to a second injection in the contralateral muscle 30 days later (indicated on the graph by a black arrow), with 2 Â 10 9 vg of the same rAAV-muSEAP (readministration), an alternative serotype (cross-administration) or PBS. The mice were killed 30 days after the second injection. Retro-orbital blood samples were collected for muSEAP quantification throughout the experiment (60 days in total). The data represent serum levels of muSEAP (mean7s.d.) measured by a chemiluminescent assay.
Multiple administrations of rAAV in muscle C Rivière et al days+PBS, killed at 60 days) and a double injection (rAAV A +rAAV A at 30 days, killed at 60 days). We performed three independent experiments and a typical result is shown in Figure 5 .
Although we observed some variation, sera from animals that received a single rAAV1 injection exhibited NAB titers ranging from 1000 to 2000 at 60 days postinjection (Figure 5a ). Upon readministration, all animals receiving the second dose of vector showed a boosted humoral response, leading to NAB titers ranging from 5000 to 6000 for the three types of vector (Figure 5a ). These high NAB levels suggest that a further readministration would likely be inefficient.
Finally, the nearly absent cross-neutralization observed in vivo by measuring the luciferase expression was further supported by a virus neutralization assay, since none of the sera from a mouse injected with a given serotype neutralized in vitro a different serotype vector (not shown).
Discussion
In this study, we evaluated the humoral immune response generated by intramuscular delivery of pseudotyped rAAV1, rAAV2 and rAAV5 in immunocompetent mice. Our main interest was to investigate the efficiency of repeated vector administration. To our knowledge, this study is the first direct comparative study of both long-term and multiple administrations after intramuscular delivery of these three serotypes in immunocompetent mice.
Pseudotyped vectors based on AAV2 recombinant genomes were generated and compared in vivo in mice. We showed that rAAV1 and rAAV5 directed long-term expression with transduction levels 12-fold and 2-fold higher than rAAV2. These data are in agreement with previous reports, thereby reinforcing AAV1 as the serotype conferring the highest transduction level in Figure 5 Effect of readministration of rAAV1, rAAV2 and rAAV5 on the generation of NAB. NAB against AAV vectors from mice with (a) single administration and (b) readministration (n ¼ 3) were titrated at killing ((a) 60 days after the single injection and (b) 60 days after the first injection and 30 days after the second injection). For each group, seven-fold serial dilutions of sera were incubated with recombinant virus of identical serotype encoding the luciferase gene. Residual AAV infectivity was then measured in HeLa cells (m.o.i. 1000 vg/cell) at 48 h post-infection. Antibody titers are given as reciprocals of the highest serum dilution, leading to a 50% decrease of infectivity. , individual value; K, mean value. A typical experiment is shown (two independents were performed). Multiple administrations of rAAV in muscle C Rivière et al skeletal muscle, along with AAV6 and the recently isolated AAV serotypes 7 and 8. 15, 16, 19, 20, 24, 28 Interestingly, in the present study, we observed transduction efficiency with rAAV1 at doses of viral particles as low as 6 Â 10 8 vg, which is significantly lower than what was used in other studies (10 11 vg). 15 The superiority of rAAV1 for muscle transduction may be explained by various factors, including the abundance of its yet unidentified receptor(s), and improved cellular trafficking and/or nuclear delivery of the viral particle.
Previous observations showed that the host immune response to the AAV2 capsid is primarily humoral and could decrease the efficiency of repeated administration. 12 It was therefore important to determine if viral capsids derived from alternative AAV serotypes could promote a humoral immune response in the host and to what extent. We therefore measured the persistence of NAB in the serum of the long-term injected mice. We observed that the persistence of NAB toward the viral particles was serotype dependent and correlated with the injected dose. Whereas only 2 Â 10 8 vg of rAAV2 was sufficient to elicit a detectable NAB response, which was still present 1 year after injection, a 3-fold higher dose of rAAV1 did not elicit any NAB, indicating that a higher dose would be required to detect similar NAB levels. In contrast, 1 year after rAAV5 administration, only very weak antibody titers were detected, even with the highest vector dose. These data suggest that, despite a high homology between capsid amino acids of AAV1 and AAV2 (about 80%), vector particles show some degree of variation in their immunogenicity. In agreement with our present observation, a recent study that has led to the discovery of novel AAV strains in Rhesus monkeys showed that minor changes in the capsid structure were sufficient to cause modifications not only in tropism but also in immune reactivity. 34 We then evaluated the feasibility and the efficiency of rAAV1, rAAV2 and rAAV5 re-or cross-administration in mouse muscle. The possibility of enhancing gene transfer was investigated by performing two administrations at a 1-month interval of either the same serotype or different ones, using vectors expressing the same reporter gene. A systematic analysis of all the combinations showed that only a secondary injection of rAAV1, after a prior rAAV2 or rAAV5 injection, results in an increased gene transfer level. These results argue in favor of an absent or minimal inhibitory immune response induced by serotypes 2 and 5 against serotype 1, and indicated that rAAV1 can further increase gene transfer level following an initial rAAV2 or rAAV5 intramuscular administration.
To further evaluate the efficacy of the second injection and focus our study on the humoral response against the AAV vector only, we performed a similar experiment, but with the first and second vectors bearing different reporter genes (muSEAP and Luc, respectively). When the first and second vectors were of identical serotype, all three rAAV1, rAAV2 and rAAV5 displayed a 1-2 log inhibition of gene expression from the second vector. Importantly, only rAAV1 readministration yielded a sustained level of gene expression, although 1 log lower. These results contrast with a previous report showing a total blockade of rAAV1 upon readministration in muscle. 24 This discrepancy may be explained by the 10-fold higher vector dose used by these authors (5 Â 10 10 vg), which would be likely to elicit a stronger immune response, thereby reducing the efficacy of the second injection. Similarly, rAAV2 and rAAV5 serotypes were inhibited upon readministration over a similar range of 2 log, reducing the expression to background levels. Altogether, these data suggest that rAAV1 might be a moderately immunogenic vector and, because of its high gene transfer performance, remains a potential candidate for multiple administrations. NAB titers against rAAV1 and rAAV2, measured at 30 days postinjection, were correlated with the efficiency of these serotypes to mediate gene transfer after readministration. No such correlation was observed for rAAV5, for which readministration was inefficient. Low levels of self-NAB against rAAV5 have been previously described, 35 together with relative inefficiency of rAAV5 readministration in muscle. 32 The basis of this observation remains to be determined and suggests that other mechanisms are involved, such as a cellular immune response. The capability of AAV to infect antigenpresenting cells (APC) is still unclear. While rAAV2 is not able to transduce mature mouse dendritic cells, 36 it was shown to transduce immature dendritic cells following intramuscular injection. 37 Moreover, crosspresentation of viral peptides from infected cells to APC can occur in muscle. 38 Whether similar pathways of cellular immunity activation through direct or indirect dendritic cell infection exist with AAV1 and AAV5 remains to be established.
Using our dual reporter system, we showed that a second administration of a different serotype-based rAAV was fully efficient, indicating that cross-administration of rAAV1, rAAV2 and rAAV5 is a very efficient approach for skeletal muscle gene transfer. No significant inhibitory cross-reaction was observed among these three serotypes. This result differs from observations made in the liver 35 and may be related to the route of administration, which has been shown to strongly impact the immune response to AAV2. 39, 40 This absence of a cross-inhibitory effect following intramuscular rAAV delivery is very encouraging, since a potential limitation of gene therapy efficiency might be the consequence of pre-existing immunity in the patient due to an initial virus exposure.
The observations reported here are limited to the intramuscular route of delivery, as our primary aim was to evaluate the possibility of multiple administrations via this route for future clinical trials. However, humoral and cellular immune responses have been shown to be dependant on the route of administration. 39, 41 Therefore, similar studies based on other modes of administration remain to be carried out. Furthermore, we have used the common laboratory Balb/c mouse strain as a model, although the genetic background has been shown to impact the immune responsivess, as shown with rAAV2. 42 However, although limited to one animal model, the observation reported here may serve as a basis to further evaluate multiple administration protocols in other strains of mice and larger animal models.
Recent studies with rAAV1 have shown the development of an immune response against the transgene product (homologous erythropoietin), due to a break of immune tolerance after delivery in skeletal muscle in non-human primates. 43, 44 It is not clear if this phenomenon is due to overexpression of a self protein or if the vector has somehow contributed to the immune resMultiple administrations of rAAV in muscle C Rivière et al ponse. However, the main concern in these studies is whether transfer of a gene expressing a self-antigen as the therapeutic protein produced at high levels from an ectopic site may be deleterious, leading to an autoimmune disease. Nevertheless, data reported in hemophilic mouse have recently shown that neutralizing antibodies initially generated following delivery of high dose of rAAV1 eventually disappeared. 17 This observation suggests that induction of immune tolerance to the neo-antigen encoded by the vector may be obtained.
Questions remain concerning the persistence of humoral immunity, and it will be crucial to determine the optimal delay between two injections in a multiple administration protocol, in conjunction with the route of administration. Multiple administration approaches could provide a means to maintain gene therapy efficacy over a very long time or to sequentially treat whole groups of muscles by regional perfusion. 45, 46 An increased NAB activity has been observed in hemophilia B patients with pre-existing immunity against AAV2, in whom anti-AAV2 antibodies titers rose by 2 to 3 log following vector injection. 10 In this respect, the low prevalence of antibodies against AAV1 in the human population 24 is likely to represent a strong advantage to circumvent pre-existing immunity in clinical trials.
Based on the initial observation pointing to rAAV1 as a very efficient vector for gene transfer to skeletal muscle in dogs 17 and non-human primates, 5,43 our present results provide new information relative to sequential administration that remain to be validated in larger animal models. Collectively, our data strongly support the view that rAAV1-based muscle gene transfer allows high and sustained gene expression, associated with moderate anti-vector immune reactivity upon readministration and no significant cross-reactivity in mice previously exposed to another serotype. Skeletal muscle delivery using rAAV2 has been evaluated in humans in phase I clinical trials, 7, 8 but insufficient levels of expression were achievable in humans using rAAV2. Our data and those of others 5, 17, 43 point to rAAV1 as a vector of choice to improve the efficiency of gene transfer protocols in human skeletal muscle, provided that the therapeutic gene product, once expressed at a sufficient level to induce a phenotypic correction, would not be per se a major source of immunotoxicity.
Materials and methods

Production of pseudotyped adeno-associated viral vectors
Pseudotyped AAV vectors were generated by packaging AAV2-based recombinant genomes in AAV1, AAV2 or AAV5 capsids. Adenovirus-free AAV2/1 and AAV2/2 vectors were generated using a three-plasmid transfection protocol as described 47 with minor modifications. Briefly, HEK293 cells were tri-transfected with the adenovirus helper plasmid pXX6, 48 a pAAV packaging plasmid expressing the rep and cap genes, and a pAAV2 vector plasmid, pSMD2-CMV-Luc (encoding for firefly luciferase) or pGG2-CMV-muSEAP (encoding a secreted form of the murine alkaline phosphatase), both under the transcriptional control of the IE CMV promoter. Packaging plasmids were pACG2.1 for rAAV2 49 and pLT-RC02 for AAV1, where the AAV2 rep gene is fused with AAV1 cap gene (a kind gift from R Mulligan, Harvard University, Boston, USA). To generate rAAV5, the same procedure was applied, except that the transfection was based on a four-plasmid system, with the packaging system split into two plasmids: pMTRep2 encoding AAV2 Rep proteins (a kind gift from D Miller, University Washington, Seattle, Washington, DC, USA) 50 and pAAV5svori expressing AAV5 Rep and Cap proteins (a kind gift from J Chiorini, Iowa University). 27 Recombinant vectors were purified by double-CsCl ultracentrifugation followed by dialysis against sterile PBS. Physical particles were quantified by Dot Blot in comparison to a standard plasmid range 51 and vector titers are expressed as vg/ml.
Intramuscular adeno-associated viral vector delivery
Female Balb/c mice (IFFA-Credo), 6-8-week old, were anesthetized by intraperitoneal injection of 100 mg of ketamine and 10 mg of xylazine per kilogram of body weight. Tibialis anterior muscles were injected with 25 ml of rAAV1, rAAV2, rAAV5 or a saline solution (PBS). In the dose-response study, three groups of animals received 2 Â 10 9 , 6.6 Â 10 8 and 2.2 Â 10 8 vg of each vector and mice were followed up to 1 year after injection. Readministration and cross-administration experiments were performed as follows: the initial injection of 2 Â 10 9 vg of rAAV in a volume of 25 ml was performed on day 1. The second rAAV injection, 2 Â 10 9 vg in 25 ml, was performed 4 weeks later in the contralateral TA and the mice were killed 4 weeks after the second injection. For transduction analysis, the mice were killed and TA muscles were harvested, frozen in nitrogen-cooled isopentane and transferred to liquid nitrogen prior to histological and enzymatic assay.
All animal procedures and care were performed in accordance with regulatory guidelines.
In vivo transduction efficiency analysis
Quantification of circulating muSEAP was carried out by retro-orbital blood sampling and chemiluminescent detection of enzyme activity. Briefly, samples were centrifuged for 5 min at 2500 g to collect sera, endogenous alkaline phosphatase was heat inactivated for 5 min at 651C and the heat-resistant muSEAP was measured by addition of the reaction buffer and CSPD s chemiluminescent substrate, according to the manufacturer's instructions (Tropix, Applied Biosystems, Forster City, USA). Chemiluminescence was quantified using a luminometer (Mediators Diagnostika, Austria). Expression levels are expressed as ng of muSEAP per ml of serum using a standard curve of purified human placental alkaline phosphatase.
MuSEAP histochemical detection on transduced muscle sections was performed as follows: mice were killed and TA muscles were harvested, embedded in optimum cutting temperature compound (Tissue-Tek, Electron Microscopy Sciences, Hatfield, UK) and sliced into 8 mm sections. After fixation in 0.5% glutaraldehyde, muscle sections were washed twice with PBS and endogenous alkaline phosphatase was heat-inactivated for 30 min at 651C. Sections were then incubated for 5 h at 371C in 0.165 mg/ml 5-bromo-4-chloro-3-indolylphosphate and 0.33 mg/ml of nitroblue tetrazolium in Multiple administrations of rAAV in muscle C Rivière et al Sections were counterstained with nuclear fast red, and inflammation and muscle integrity were evaluated by hematoxylin-eosin staining and light microscopy analysis.
Luciferase quantification assay. Frozen muscles were lysed in 500 ml of lysis buffer (25 mM Tris-phosphate, 1 mM dithiothreitol, 1 mM ethylenediamine tetraacetate (EDTA), 15% glycerol, 8 mM MgCl 2 , 0.2% Triton X-100) containing a cocktail of protease inhibitor (Sigma, St Louis, USA). The organs were first homogenized for 30 s with an Ultra-Turrax and then submitted to three successive homogenizations to achieve complete lysis. Cell membranes and debris were pelleted by centrifugation for 10 min at 10 000 g at 41C. In all, 5 or 25 ml of the supernatant was mixed with 100 ml of assay buffer (25 mM Tris-phosphate, 1 mM dithiothreitol, 1 mM EDTA, 15% glycerol, 8 mM MgCl 2 , 2 mM adenine triphosphate) and 100 ml of 167 mM luciferin (Molecular Probes, Leiden, NL). The luciferase expression was measured for 10 s with a luminometer (Mediators Diagnostika). Expression level is expressed as relative light units (RLU, 1 RLU ¼ 10 photons) per second per well and standardized according to the weight of the sample (mg).
Cell culture
Human cervical carcinoma HeLa cells were cultured in a 5% CO 2 atmosphere at 371C in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL, Paisley, UK) supplemented with 2 mM L-glutamine and 10% heatinactivated fetal calf serum (FCS, Hyclone, Perbio, Brebiereo, France).
Virus neutralization assay
Serum samples collected from mice were incubated at 561C for 30 min to inactivate complement. Recombinant AAV-luc (10 8 vg) was diluted in serum-free DMEM and incubated for 1 h at 371C with the sera serially diluted (1/20, 1/200, 1/400, 1/800, 1/1600 and 1/3200). The virus-serum mixtures (200 ml) were added to HeLa cells in 48-well plates (10 5 cell/well) at a m.o.i. of 1000 vg/cell and complemented with 300 ml of DMEM-10% FCS. After 24 h of incubation at 371C, the infection medium was replaced with 500 ml of fresh DMEM-10% FCS medium, and the cells were further incubated for 24 h. Luciferase expression was quantified as described in the previous section, except that cells were lysed in 250 ml of lysis buffer without protease inhibitors and 50 ml of the supernatant was submitted to analysis. All the values are given as RLU/s/well and are standardized by the protein content of the sample quantified with the Biorad Protein Assay detection kit. The NAB titers were defined as the reciprocal serum dilution inhibiting transduction by 50% (the negative control was a PBS-injected mouse serum).
Statistical analysis
A two-way ANOVA was performed for the readministration/cross-administration study (Figure 4 ) with two factors: (i) effect of re-injection of the same serotyped rAAV versus effect of re-injection of a different serotyped rAAV and (ii) the experiment factor.
